Trials

University Hospitals Birmingham NHS Foundation Trust is a regional and national centre for specialist clinical services.

It is home to some of the country’s leading clinical research institutions, and is dedicated to developing and implementing groundbreaking treatments, technologies and techniques.

  • The consequences of SDHA fusion gene on tumorigenesis and tumour metabolism in well differentiated retroperitoneal liposarcoma

    View Trial
  • SOLAR: A Phase 2 Randomized Open-label Parallel-group Active Comparator Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL) Mycosis Fungoides (MF) Subtype

    View Trial
  • Dietary management clinical status and outcome of patients with Citrin deficiency in the UK

    View Trial
  • PARCT

    Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

    View Trial
  • SPECTA

    SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

    View Trial
  • PROCLIPI

    Multicenter Observational Prospective Study for the Identification of Prognostic Factors in Patients With Mycosis Fungoides/sezary Syndrome: Proposal for An International Prognostic Index for Cutaneous Lymphoma

    View Trial
  • 035 Continuation study

    An open-label treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma systemic anaplastic large cell lymphoma or CD30-positive cutaneous T-cell lymphoma

    View Trial
  • Investigating the immune response to haematological malignancies with a view to novel therapies

    View Trial
  • Functional Imaging of Tumours

    View Trial
  • RESMAIN

    A multicentre double blind randomised placebo-controlled Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

    View Trial